ISSN: 2161-0460

Revista de enfermedad de Alzheimer y parkinsonismo

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Indexado en
  • Índice Copérnico
  • Google Académico
  • sherpa romeo
  • Abrir puerta J
  • Revista GenámicaBuscar
  • Claves Académicas
  • TOC de revistas
  • Infraestructura Nacional del Conocimiento de China (CNKI)
  • Biblioteca de revistas electrónicas
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catálogo en línea SWB
  • Biblioteca Virtual de Biología (vifabio)
  • publones
  • Fundación de Ginebra para la educación y la investigación médicas
  • Pub Europeo
  • ICMJE
Comparte esta página

Abstracto

Response of �?±-Synuclein Expression to Amyloid �?²40 and Amyloid �?²42 administration into Rat Brain

Mishra N, Kumar P, Singh R1 and Sharma D

Objective: In the present study, we assessed the change in α-synuclein expression upon stereotaxic administration of pre-aggregated amyloid (Aβ40 and Aβ42) in the hippocampus and amygdala of the rat brain.

Method: Forty-eight, male Wistar rats, 6 months of age at the beginning of the experiment, were divided into 8 groups, containing 6 animals in each group. Group 1: saline injected into the hippocampus (Aβ40 Hippocampus Control). Group 2: aggregated-Aβ40injected into the hippocampus (Aβ40 Hippocampus Test). Group 3: saline injected into the amygdala (Aβ40 Amygdala Control). Group 4: aggregated-Aβ40 injected into the amygdala (Aβ40 Amygdala Test). Group 5: 16.7%DMSO in distilled water injected into the hippocampus (Aβ42 Hippocampus Control). Group 6: aggregated-Aβ42 oligomer was injected into the hippocampus (Aβ42 Hippocampus Test). Group 7: 16.7%DMSO in distilled water injected into the amygdala (Aβ42 Amygdala Control). Group 8: aggregated-Aβ42 administered into the amygdala (Aβ42Amygdala Test). Animals of each group were sacrificed by cervical dislocation (n=6) and transcardial perfusion (n=4) for molecular experiments (real-time PCR and western blotting) and histological studies, respectively. Brains were micro-dissected into amygdala, hippocampus, cortex, cerebellum, medulla, and midbrain for the molecular experiments.

Results: We found that there was an increase in the expression of α-synuclein, both at the gene and protein levels, in the hippocampus and cortex of the amyloid injected animals. Aβ42 seemed to produce a quantitatively greater effect than Aβ40.

Conclusion: Therefore, it can be extrapolated that increased expression of amyloid precursor protein (APP) gene can lead to the increase in expression of α-synuclein, leading to greater neurotoxicity in neurodegenerative disorders caused by APP overexpression (such as AD).